JP2012516355A5 - - Google Patents

Download PDF

Info

Publication number
JP2012516355A5
JP2012516355A5 JP2011548305A JP2011548305A JP2012516355A5 JP 2012516355 A5 JP2012516355 A5 JP 2012516355A5 JP 2011548305 A JP2011548305 A JP 2011548305A JP 2011548305 A JP2011548305 A JP 2011548305A JP 2012516355 A5 JP2012516355 A5 JP 2012516355A5
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
optionally substituted
hydrogen
nitrile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011548305A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012516355A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/022430 external-priority patent/WO2010088406A1/en
Publication of JP2012516355A publication Critical patent/JP2012516355A/ja
Publication of JP2012516355A5 publication Critical patent/JP2012516355A5/ja
Withdrawn legal-status Critical Current

Links

JP2011548305A 2009-01-28 2010-01-28 mGLuR4アロステリック増強剤としての置換された1,1,3,3−テトラオキシドベンゾ[d][1,3,2]ジチアゾール、組成物、および神経機能不全を治療する方法 Withdrawn JP2012516355A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20627109P 2009-01-28 2009-01-28
US61/206,271 2009-01-28
PCT/US2010/022430 WO2010088406A1 (en) 2009-01-28 2010-01-28 Substituted 1,1,3,3-tetraoxidobenzo[d][1,3,2]dithiazoles as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction

Publications (2)

Publication Number Publication Date
JP2012516355A JP2012516355A (ja) 2012-07-19
JP2012516355A5 true JP2012516355A5 (cg-RX-API-DMAC7.html) 2013-04-11

Family

ID=42396011

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011548305A Withdrawn JP2012516355A (ja) 2009-01-28 2010-01-28 mGLuR4アロステリック増強剤としての置換された1,1,3,3−テトラオキシドベンゾ[d][1,3,2]ジチアゾール、組成物、および神経機能不全を治療する方法

Country Status (8)

Country Link
US (1) US8658650B2 (cg-RX-API-DMAC7.html)
EP (1) EP2393785A4 (cg-RX-API-DMAC7.html)
JP (1) JP2012516355A (cg-RX-API-DMAC7.html)
AU (1) AU2010208176A1 (cg-RX-API-DMAC7.html)
CA (1) CA2751176A1 (cg-RX-API-DMAC7.html)
IL (1) IL214337A0 (cg-RX-API-DMAC7.html)
SG (1) SG173465A1 (cg-RX-API-DMAC7.html)
WO (1) WO2010088406A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2737699A1 (en) * 2008-09-16 2010-03-25 Merck Sharp & Dohme Corp. Phthalimide derivative metabotropic glutamate r4 ligands
US8759377B2 (en) 2009-11-23 2014-06-24 Vanderbilt University Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
EP2853532B1 (en) 2013-09-28 2020-12-09 Instytut Farmakologii Polskiej Akademii Nauk 1,2,4-oxadiazole derivatives as allosteric modulators of metabotropic glutamate receptors belonging to group III
KR102286233B1 (ko) * 2013-10-22 2021-08-06 코르테바 애그리사이언스 엘엘씨 살충 조성물 및 관련 방법
US10221172B2 (en) 2015-01-13 2019-03-05 Vanderbilt University Benzothiazole and benzisothiazole-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US10227343B2 (en) 2015-01-30 2019-03-12 Vanderbilt University Isoquiniline and napthalene-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
WO2016123629A1 (en) 2015-01-30 2016-08-04 Vanderbilt University Indazole and azaindazole substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
WO2016179351A1 (en) 2015-05-05 2016-11-10 Northwestern University Treatment of levodopa-induced dyskinesias
CA3015345A1 (en) 2016-02-23 2017-08-31 Indiana University Research & Technology Corporation Combination therapies for treatment of spinal muscular atrophy
US10710997B2 (en) 2016-09-01 2020-07-14 Vanderbilt University Isoquinoline amide and isoquinoline amide-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US10294222B2 (en) 2016-09-01 2019-05-21 Vanderbilt University Benzomorpholine and benzomorpholine-substituted compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US11242342B2 (en) 2016-11-08 2022-02-08 Vanderbilt University Isoquinoline amine compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US10968227B2 (en) 2016-11-08 2021-04-06 Vanderbilt University Isoquinoline ether compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
WO2019006157A1 (en) 2017-06-28 2019-01-03 Vanderbilt University Pyridine quinoline compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
BR112020003292A2 (pt) 2017-08-16 2020-08-18 Vanderbilt University compostos indazol como potencializadores alostéricos de mglur4 e seus usos terapêuticos, bem como composição farmacêutica e método para fabricação de medicamento para potenciar a atividade do receptor mglur4
KR102024361B1 (ko) * 2017-09-26 2019-09-23 울산과학기술원 벤젠 디아민 유도체를 포함하는 퇴행성 뇌질환 예방 또는 치료용 조성물

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3321969A1 (de) 1983-06-18 1984-12-20 Troponwerke GmbH & Co KG, 5000 Köln 2-pyrimidinyl-1-piperazin-derivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
US5187276A (en) * 1983-06-18 1993-02-16 Troponwerke Gmbh & Co. Kg. 2-pyrimidinyl-1-piperazine derivatives
AUPR738301A0 (en) 2001-08-30 2001-09-20 Starpharma Limited Chemotherapeutic agents
US7223788B2 (en) * 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
US20060166972A1 (en) 2003-07-11 2006-07-27 Conn P J Treatment of movement disorders with a metabotropic glutamate 4 receptor positive allosteric modulator
WO2005051488A1 (en) 2003-11-26 2005-06-09 Pfizer Products Inc. Combination of dopamine agonists and monoamine reuptake inhibitors
US20060004001A1 (en) 2004-02-27 2006-01-05 Merz Pharma Gmbh & Co., Kgaa Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors
WO2008066887A2 (en) * 2006-11-30 2008-06-05 Albert Einstein College Of Medicine Of Yeshiva University Small molecule inhibitors of bcl6
CA2737699A1 (en) 2008-09-16 2010-03-25 Merck Sharp & Dohme Corp. Phthalimide derivative metabotropic glutamate r4 ligands
JP2013500267A (ja) 2009-07-23 2013-01-07 ヴァンダービルト ユニバーシティー mGLuR4増強剤としての置換されたベンゾイミダゾールスルホンアミド類および置換されたインドールスルホンアミド類
RU2012114770A (ru) 2009-09-04 2013-10-10 Вандербилт Юниверсити АЛЛОСТЕРИЧЕСКИЕ СРЕДСТВА ПОТЕНЦИРОВАНИЯ mGluR4, КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ ДИСФУНКЦИЙ
BR112012009576A2 (pt) 2009-10-22 2019-09-24 Univ Vanderbilt potencializador alostérico de mglur4, composições, e métodos de tratamento de disfunção neurológica
AU2010314891A1 (en) 2009-11-06 2012-06-07 Vanderbilt University Aryl and heteroaryl sulfones as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
CA2789434A1 (en) 2010-02-11 2011-08-18 Vanderbilt University Benzisoxazoles and azabenzisoxazoles as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
EP2533639A4 (en) 2010-02-11 2013-08-21 Univ Vanderbilt PYRAZOLOPYRIDIN, PYRAZOLOPYRZIN, PYRAZOLOPYRIMIDIN, PYRAZOLOTHIOPHEN AND PYRAZOLOTHIAZOL COMPOUNDS AS ALLOSTERIC MGLUR4 POTENTRANS AND COMPOUNDS AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTIONS
CN102939006A (zh) 2010-05-12 2013-02-20 范德比尔特大学 杂环砜基代谢型谷氨酸受体第4亚型(mglur4)变构增效剂,组合物,以及用以治疗神经性障碍的方法

Similar Documents

Publication Publication Date Title
JP2012516355A5 (cg-RX-API-DMAC7.html)
JP2010510177A5 (cg-RX-API-DMAC7.html)
JP2010083862A5 (cg-RX-API-DMAC7.html)
JP2013102146A5 (ja) 化合物
AR124117A2 (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes
JP2014029971A5 (ja) 有機化合物
JP2012087114A5 (ja) カルバゾール誘導体
JP2014209611A5 (ja) 化合物
JP2014526533A5 (cg-RX-API-DMAC7.html)
JP2013519685A5 (cg-RX-API-DMAC7.html)
JP2013010731A5 (ja) 複素環化合物
JP2013519684A5 (cg-RX-API-DMAC7.html)
JP2012140436A5 (ja) 物質
JP2011006405A5 (ja) 化合物
JP2013010749A5 (ja) カルバゾール化合物
JP2011527667A5 (cg-RX-API-DMAC7.html)
JP2013100341A5 (cg-RX-API-DMAC7.html)
JP2015042636A5 (ja) 有機化合物
JP2015063518A5 (ja) 有機化合物
JP2005289914A5 (cg-RX-API-DMAC7.html)
JP2010095546A5 (cg-RX-API-DMAC7.html)
JP2012515776A5 (cg-RX-API-DMAC7.html)
JP2012006912A5 (ja) トリアゾール誘導体
JP2010504286A5 (cg-RX-API-DMAC7.html)
JP2015508092A5 (cg-RX-API-DMAC7.html)